DR3 Antibody
| Code | Size | Price |
|---|
| PSI-1158-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-1158-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
DR3 Antibody: DR3, TR3, DDR3, LARD, APO-3, TRAMP, WSL-1, WSL-LR, TNFRSF12, APO3, DR3, WSL, WSL1, UNQ455/PRO779, Tumor necrosis factor receptor superfamily member 25, Apo-3
Application Note:
DR3 antibody can be used for detection of DR3 expression by Western blot at 1 μg/mL. 59 kDa band should be detected. Antibody can also be used for immunocytochemistry starting at 10 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
DR3 Antibody: Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including TNF and Fas ligand of the TNF family through their death domain containing receptors, TNFR1 and Fas. A novel cell death receptor was recently identified by several groups independently and designated DR3, Wsl-1, Apo-3, TRAMP and LARD1-5. The ligand for this novel death receptor has been defined as TWEAK, also termed Apo3L. DR3 is highly expressed in the tissues enriched in lymphocytes including PBL, thymus and spleen. Like TNFR1, DR3 induces apoptosis and NF-κB activation.
Background References:
- Chinnaiyan AM; O'Rourke K; Yu GL; Lyons RH; Garg M; Duan DR; Xing L; Gentz R; Ni J; Dixit VM. Science, 1996;274:990-2.
- Kitson J; Raven T; Jiang YP; Goeddel DV; Giles KM; Pun KT; Grinham CJ; Brown R; Farrow SN. Nature, 1996;384:372-5.
- Marsters SA; Sheridan JP; Donahue CJ; Pitti RM; Gray CL; Goddard AD; Bauer KD; Ashkenazi A. Curr Biol, 1996;6:1669-76.
- Bodmer JL; Burns K; Schneider P; Hofmann K; Steiner V; Thome M; Bornand T; Hahne M; Schroter M; Becker K; et al. Immunity, 1997;6:79-88.
Buffer:
DR3 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/ml
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
DR3 antibody was raised against a peptide corresponding to amino acids in extracellular domain of human DR3 precusor.
The immunogen is located within amino acids 50 - 100 of DR3.
The immunogen is located within amino acids 50 - 100 of DR3.
NCBI Gene ID #:
8718
NCBI Official Name:
tumor necrosis factor receptor superfamily, member 25
NCBI Official Symbol:
TNFRSF25
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
59 kDa
Protein Accession #:
AAQ88676
Protein GI Number:
37181738
Purification:
DR3 Antibody is affinity chromatography purified via peptide column.
Research Area:
Apoptosis
Swissprot #:
Q93038
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | DR3 Peptide | PSI-1158P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|